---
title: "Verona Pharma Completes Acquisition and Delisting Process"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/260154801.md"
description: "Verona Pharma has completed its acquisition process, sanctioned by the High Court of Justice of England and Wales on October 6, 2025. Shareholders received cash for their shares, and the company's ADSs were delisted from Nasdaq. The board of directors resigned, and new executives were appointed. Analysts rate VRNA stock as Hold with a $107.00 price target, citing strong revenue growth but noting profitability challenges and high valuations. The current market cap is $9.19B, with a technical sentiment signal of Buy."
datetime: "2025-10-07T11:29:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/260154801.md)
  - [en](https://longbridge.com/en/news/260154801.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/260154801.md)
---

# Verona Pharma Completes Acquisition and Delisting Process

Verona Pharma ( (VRNA) ) has shared an announcement.

On October 6, 2025, the High Court of Justice of England and Wales sanctioned the Scheme of Arrangement for Verona Pharma, leading to the acquisition of all issued and outstanding ordinary shares by Bidco. This transaction was completed on October 7, 2025, resulting in shareholders receiving cash consideration for their shares and American Depositary Shares. Following this transaction, Verona Pharma’s ADSs were delisted from Nasdaq, and the company plans to terminate its registration and suspend reporting obligations. Additionally, the company’s board of directors resigned, and new executive officers were appointed.

The most recent analyst rating on (VRNA) stock is a Hold with a $107.00 price target. To see the full list of analyst forecasts on Verona Pharma stock, see the VRNA Stock Forecast page.

**Spark’s Take on VRNA Stock**

According to Spark, TipRanks’ AI Analyst, VRNA is a Neutral.

Verona Pharma’s stock is bolstered by strong revenue growth and a successful product launch, contributing to positive momentum. However, profitability challenges, high valuations, and potential overbought conditions temper enthusiasm. The company’s improved financial flexibility is a key strength, though ongoing operating losses and high SG&A expenses are notable risks.

To see Spark’s full report on VRNA stock, click here.

**More about Verona Pharma**

**Average Trading Volume:** 3,558,546

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $9.19B

For a thorough assessment of VRNA stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [VRNA.US](https://longbridge.com/en/quote/VRNA.US.md)

## Related News & Research

- [Telecom Stocks: What SpaceX IPO Filing Revealed About Starlink's Big Ambitions](https://longbridge.com/en/news/287245743.md)
- [FACTBOX-IPO-bound SpaceX's board is stacked with Musk empire loyalists](https://longbridge.com/en/news/287206089.md)
- [INSTANT VIEW-SpaceX files long awaited IPO, creating a fresh AI play](https://longbridge.com/en/news/287124128.md)
- [ANALYSIS-Why SpaceX's mega IPO may not signal a broader rebound in listings](https://longbridge.com/en/news/287215490.md)
- [GRAPHIC-Major takeaways from Magnificent Seven's AI-fueled earnings](https://longbridge.com/en/news/287224928.md)